Developer docs
API playgroundTry for free, no card

Search company profiles

Deciphex

Full company profile

uuid00004e6

Namestring
Deciphex
Legal namestring
Deciphex Holdings Limited
Websiteurl
deciphex.com
Company typeenum
Private
Founded yearint
2017
Descriptiontext

Deciphex is a Dublin-headquartered digital pathology company operating a dual-platform business that combines proprietary AI models with a global network of 250+ subspecialty pathologists to deliver diagnostic and preclinical research services. Its Diagnexia platform serves clinical customers, primarily NHS trusts and healthcare institutions, with per-unit CPT-based primary diagnostics and secondary consults, reducing NHS pathology wait times from approximately two months to two days and integrating with Sectra, Philips, and Leica imaging systems. Its Patholytix platform serves pharmaceutical companies and contract research organizations with GLP-compliant digital pathology workflows for preclinical safety assessments, including the Patholytix Foresight AI decision support tool (developed with Charles River Laboratories) and the first DICOM-native platform for full archival of regulated digital studies.

The company monetizes through recurring per-case clinical billing on Diagnexia and SaaS-style subscription licensing on Patholytix, supported by value-added AI workflow services. Deciphex processes approximately 97,000 cases annually across its network and reports adoption by 27+ NHS trusts and 9 of the top 10 global pharmaceutical companies, with strategic co-development and validation partnerships with Charles River Laboratories and Novartis. Its foundation AI models are trained on one of the world's largest digital pathology image repositories, augmented by the EU BigPicture consortium's three-million-slide repository.

Since founding in 2017 by Donal O'Shea, Deciphex has scaled to approximately 223 employees across Ireland, the UK, US, Canada, and Switzerland, accumulated a dense regulatory footprint (UKAS ISO 15189:2022, CAP, CQC, MHRA GLP, GDPR/HIPAA), and raised over $80M in cumulative equity and debt funding, including a $32.3M Series C led by Molten Ventures in January 2025 and a €15M venture debt facility from Claret Capital Partners in October 2025. Current strategic priorities are US market expansion and UK histopathology market leadership by 2027, supported by ongoing product investment in AI foundation models and the VICT3R initiative for animal-use reduction in preclinical studies.

Short descriptiontext

Deciphex operates a dual-platform digital pathology business combining proprietary AI models with a global network of 250+ subspecialty pathologists to serve NHS trusts via Diagnexia clinical diagnostics and top pharmaceutical companies via Patholytix GLP-compliant preclinical research workflows.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersDublin, Ireland
HQ citystring
Dublin
HQ countrystring
Ireland
HQ regionstring
Europe
Markets served

Serves global market

Offices6 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
digital pathology services, AI diagnostic software, clinical pathology platform, preclinical drug safety, histopathology reporting
Industry1 code
PRIMARYHLACAMAB
Anatomic Pathology LIS & Digital Pathology Workflow
Healthcare & Life Sciences/Digital Health & Health IT/Laboratory Information Systems (LIS/LIMS) & Pathology Informatics
NAICS code1 code
  • Medical Laboratories621511
SIC code1 code
  • Services-Medical Laboratories8071
Product category
Digital Pathology Software
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model3 records
1Diagnexia Clinical Diagnostics Services
TypeSubscription Recurring
Description

Per-case diagnostic pathology services connecting healthcare institutions to global subspecialty pathologists. Pricing based on CPT codes with per-unit activity billing. Services include primary diagnostics, secondary consultations, and turnaround time guarantees.

deciphex.com
2Patholytix Pharmaceutical Research Platform
TypeSubscription Recurring
Description

SaaS platform licensing for GLP-compliant digital pathology workflows for pharmaceutical companies and CROs. Enables faster drug compound testing and preclinical safety assessments.

deciphex.com
3AI-Enhanced Workflow Services
TypeProfessional Services
Description

Value-added services including AI decision support, quality assurance automation, and digital pathology integration that accelerate diagnostic and research workflows.

deciphex.com
Marketing channels7 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels5 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales
Pricing details2 tiers
1Per-unit activity billing for pathology services
ModelUnit PricingBilling cadencePay-as-you-go
Notes

Diagnexia rates are per unit of activity (CPT codes). Example: GI cases average 2.6 CPTs per case. Pay only when utilized - no daily rate commitments like traditional locum tenens.

deciphex.com
2Subscription-based platform access for pharmaceutical research
ModelSubscriptionBilling cadenceAnnual
Notes

Patholytix platform licensed to pharmaceutical companies and CROs for digital pathology workflows, with pricing based on usage volume and study complexity.

deciphex.com
GTM typeB2B
B2B
Offering typeSoftware
Software
Brand1 of 3 records shown
1Diagnexia
Description

Clinical digital pathology platform connecting hospitals to international network of subspecialty pathologists for rapid diagnostics and backlog reduction

deciphex.com
+2 more records
Core offering1 text field

Deciphex operates two AI-powered digital pathology platforms. Diagnexia is a clinical diagnostics service connecting hospitals and NHS trusts to a global network of 250+ subspecialty pathologists, delivering rapid histopathology reporting with AI-driven quality controls. Patholytix is a GLP-compliant digital pathology platform for pharmaceutical companies and CROs that enables end-to-end digital preclinical safety studies, including the Patholytix Foresight AI decision support tool co-developed with Charles River Laboratories.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 10 values shown
  • 40% faster pathologist productivity while maintaining diagnostic accuracy
+9 more records
Product overview1 text field

Deciphex operates a dual-platform business model serving distinct markets. Diagnexia is the clinical branch providing cloud-based digital pathology diagnostic services that connect hospitals to an international network of subspecialty pathologists for rapid, high-quality diagnostic reports, with fully CQC-registered facilities in Oxford and Exeter. Patholytix is the pharmaceutical research platform providing GLP-compliant digital pathology for preclinical safety assessments, enabling faster drug development through end-to-end digital studies workflows. Both platforms are powered by proprietary AI tools including Foresight for toxicologic pathology decision support, which reduce pathologist review time by over 20% and enable pathologists to work up to 40% faster.

Product and service4 records
1Diagnexia
CategoryClinical Diagnostics Platform
Description

Clinical digital pathology platform providing world-class diagnostic services to healthcare institutions. Connects hospitals to an international network of subspecialty pathologists for rapid, high-quality diagnostic reports with end-to-end histopathology services from specimen to digital report. Used by 27+ NHS trusts.

2Patholytix
CategoryPreclinical Research Platform
Description

GLP-compliant digital pathology platform for pharmaceutical research and preclinical safety assessments. Enables faster, more thorough testing of hundreds of drug compounds with end-to-end digital studies workflows. Used by 9 of top 10 pharmaceutical companies.

3Patholytix Foresight
CategoryAI Decision Support Tool
Description

AI-powered decision support tool for toxicologic pathology developed in partnership with Charles River Laboratories. Provides deeper insights into candidate efficacy during Lead Optimization and Dose Range Finding development stages, reducing pathologist review time by over 20%.

4Patholytix 4.0
CategoryDigital Pathology Platform
Description

First DICOM-native platform for full archival and reconstruction of regulated digital studies, ensuring long-term accessibility and interoperability of GLP study data with native DICOMWSI for standardized digital slide storage.

Scale indicator16 records

Each record includes

Type, Value, Description, Source

Partnership6 partners
Strategic tierStrategicTypeTechnology or IntegrationAnnounced on2025-06-20
Description

Collaboration to enable UK patients access to Artera's groundbreaking prostate cancer assay that combines hidden morphological signatures from digital pathology images with clinical findings for instant prognostic output.

Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2025-01-07
Description

Major strategic partnership since March 2020 for co-development of AI tools to accelerate drug safety assessment. Completed first fully digital GLP study in May 2022. Strategic investor and commercial partner; collaborator on Patholytix Foresight AI decision support tool.

3VICT3R Initiative Partners (33 organizations)
Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2024-09-16
Description

Public-private partnership led by Pompeu Fabra University and Bayer AG. €28M IHI JU-funded initiative developing Virtual Control Groups to replace animals in concurrent control groups, reducing animal use by up to 25%. Deciphex contributes AI expertise for this 42-month project.

deciphex.com
Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2022-05-19
Description

Series B investor and strategic collaborator on next-generation foundational AI models for multispecies lesion detection. Provides access to extensive non-clinical datasets from multi-species safety studies for AI model training.

Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2022-05-19
Description

Partner in €2M EU Fast Track to Innovation award for AI-driven workflows for preclinical pathology. Collaboration on accelerating development of AI-based workflows for preclinical pathology.

Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2021-01-28
Description

EU IMI-funded pan-European initiative building world's largest digital pathology image repository (3 million slides) for AI model validation. Deciphex contributes to and draws from this repository for clinical and non-clinical AI development.

Recent move9 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

AI-native digital pathology company developing foundation models and diagnostic AI for clinical pathology. Directly comparable in technology stack (AI on whole-slide images), target customer (health systems and pathologists), and category leadership positioning.

TypeDirect peer
Description

AI-powered pathology platform serving both clinical diagnostics and biopharma research, including preclinical safety assessment. Closest direct competitor to Deciphex's dual Diagnexia/Patholytix model with comparable pharma partnerships.

TypeDirect peer
Description

AI-driven cancer diagnostics platform for clinical pathology, deployed in health systems across the US, Europe, and Israel. Comparable clinical-side competitor with similar AI-on-whole-slide-image approach to Diagnexia.

TypeDirect peer
Description

Digital pathology software company providing AI-enabled workflow and image management solutions to life sciences organizations and clinical labs. Comparable in platform/enterprise software positioning and customer overlap in pharma R&D.

TypeEmerging player
Description

AI biotech company with significant pathology AI initiatives (including MOSAIQ for digital pathology) and biopharma partnerships. Partial overlap in foundation model strategy and pharma data collaborations.

TypeBroad incumbent
Description

Incumbent digital pathology vendor (via Ventana/Roche) with integrated slide scanners, image management, and companion AI algorithms. Represents the primary enterprise-suite competitive threat to Deciphex's clinical workflow.

TypeBroad incumbent
Description

Incumbent vendor of enterprise digital pathology solutions, already an integration partner for Deciphex. Comparable in NHS deployments and AI strategy, but operating at much broader scale across imaging and pathology.

TypeEmerging player
Description

AI pathology company developing AI algorithms for clinical and research pathology applications. Emerging peer with overlapping AI-on-pathology focus, particularly in Europe.

TypeEmerging player
Description

Medical AI company with pathology and radiology AI products serving clinical diagnostics and pharma research. Comparable in AI-driven cancer detection and pharma partnership strategy.

TypeRegional player
Description

Major European diagnostics provider offering pathology and laboratory services across multiple countries. Comparable in clinical pathology services at scale and as a potential EU incumbent competitor to Diagnexia.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers5 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

Integration4 records

Each record includes

Title, Type, Description, Source

AI capability7 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature7 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles12 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries4 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance8 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds8 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors14 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Deciphex

Digital Pathology Softwaredeciphex.com

Deciphex operates a dual-platform digital pathology business combining proprietary AI models with a global network of 250+ subspecialty pathologists to serve NHS trusts via Diagnexia clinical diagnostics and top pharmaceutical companies via Patholytix GLP-compliant preclinical research workflows.

What Deciphex does

Deciphex is a Dublin-headquartered digital pathology company operating a dual-platform business that combines proprietary AI models with a global network of 250+ subspecialty pathologists to deliver diagnostic and preclinical research services. Its Diagnexia platform serves clinical customers, primarily NHS trusts and healthcare institutions, with per-unit CPT-based primary diagnostics and secondary consults, reducing NHS pathology wait times from approximately two months to two days and integrating with Sectra, Philips, and Leica imaging systems. Its Patholytix platform serves pharmaceutical companies and contract research organizations with GLP-compliant digital pathology workflows for preclinical safety assessments, including the Patholytix Foresight AI decision support tool (developed with Charles River Laboratories) and the first DICOM-native platform for full archival of regulated digital studies.

The company monetizes through recurring per-case clinical billing on Diagnexia and SaaS-style subscription licensing on Patholytix, supported by value-added AI workflow services. Deciphex processes approximately 97,000 cases annually across its network and reports adoption by 27+ NHS trusts and 9 of the top 10 global pharmaceutical companies, with strategic co-development and validation partnerships with Charles River Laboratories and Novartis. Its foundation AI models are trained on one of the world's largest digital pathology image repositories, augmented by the EU BigPicture consortium's three-million-slide repository.

Since founding in 2017 by Donal O'Shea, Deciphex has scaled to approximately 223 employees across Ireland, the UK, US, Canada, and Switzerland, accumulated a dense regulatory footprint (UKAS ISO 15189:2022, CAP, CQC, MHRA GLP, GDPR/HIPAA), and raised over $80M in cumulative equity and debt funding, including a $32.3M Series C led by Molten Ventures in January 2025 and a €15M venture debt facility from Claret Capital Partners in October 2025. Current strategic priorities are US market expansion and UK histopathology market leadership by 2027, supported by ongoing product investment in AI foundation models and the VICT3R initiative for animal-use reduction in preclinical studies.

Deciphex firmographics

Firmographics
Name
Deciphex
Legal name
Deciphex Holdings Limited
Website
https://deciphex.com
Company type
Private
Founded year
2017
Operating status
Operating
Headcount range
101–250 employees
Short description
Deciphex operates a dual-platform digital pathology business combining proprietary AI models with a global network of 250+ subspecialty pathologists to serve NHS trusts via Diagnexia clinical diagnostics and top pharmaceutical companies via Patholytix GLP-compliant preclinical research workflows.
Ownership category
akta.pro rank

Deciphex industry classification

Industry
Product category
Digital Pathology Software
NAICS
Medical Laboratories (621511)
SIC
Services-Medical Laboratories (8071)
akta.pro industry
PRIMARYHLACAMAB
Anatomic Pathology LIS & Digital Pathology Workflow
Healthcare & Life Sciences/Digital Health & Health IT/Laboratory Information Systems (LIS/LIMS) & Pathology Informatics

Keywords

  • Digital pathology services
  • AI diagnostic software
  • Clinical pathology platform
  • Preclinical drug safety
  • Histopathology reporting

Where Deciphex is headquartered

Location

Headquarters

HQ city
Dublin
HQ country
Ireland
HQ region
Europe

Offices6 records

Markets served

Deciphex business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales

Revenue model

  1. Diagnexia Clinical Diagnostics Services: Per-case diagnostic pathology services connecting healthcare institutions to global subspecialty pathologists. Pricing based on CPT codes with per-unit activity billing. Services include primary diagnostics, secondary consultations, and turnaround time guarantees.
  2. Patholytix Pharmaceutical Research Platform: SaaS platform licensing for GLP-compliant digital pathology workflows for pharmaceutical companies and CROs. Enables faster drug compound testing and preclinical safety assessments.
  3. AI-Enhanced Workflow Services: Value-added services including AI decision support, quality assurance automation, and digital pathology integration that accelerate diagnostic and research workflows.

Pricing tiers

ModelBillingPrice
Unit PricingPay-as-you-goPer-unit activity billing for pathology services
SubscriptionAnnualSubscription-based platform access for pharmaceutical research

Go-to-market motion1 record

Distribution channels5 records

Marketing channels7 records

Deciphex product offering

Product offering

Core offering

Deciphex operates two AI-powered digital pathology platforms. Diagnexia is a clinical diagnostics service connecting hospitals and NHS trusts to a global network of 250+ subspecialty pathologists, delivering rapid histopathology reporting with AI-driven quality controls. Patholytix is a GLP-compliant digital pathology platform for pharmaceutical companies and CROs that enables end-to-end digital preclinical safety studies, including the Patholytix Foresight AI decision support tool co-developed with Charles River Laboratories.

Product overview

Deciphex operates a dual-platform business model serving distinct markets. Diagnexia is the clinical branch providing cloud-based digital pathology diagnostic services that connect hospitals to an international network of subspecialty pathologists for rapid, high-quality diagnostic reports, with fully CQC-registered facilities in Oxford and Exeter. Patholytix is the pharmaceutical research platform providing GLP-compliant digital pathology for preclinical safety assessments, enabling faster drug development through end-to-end digital studies workflows. Both platforms are powered by proprietary AI tools including Foresight for toxicologic pathology decision support, which reduce pathologist review time by over 20% and enable pathologists to work up to 40% faster.

Differentiator

Problem solved

Functional benefit

Brands

  • Diagnexia: Clinical digital pathology platform connecting hospitals to international network of subspecialty pathologists for rapid diagnostics and backlog reduction
  • Patholytix
  • Patholytix Foresight

Products and services

  • Diagnexia Clinical digital pathology platform providing world-class diagnostic services to healthcare institutions. Connects hospitals to an international network of subspecialty pathologists for rapid, high-quality diagnostic reports with end-to-end histopathology services from specimen to digital report. Used by 27+ NHS trusts.
  • Patholytix GLP-compliant digital pathology platform for pharmaceutical research and preclinical safety assessments. Enables faster, more thorough testing of hundreds of drug compounds with end-to-end digital studies workflows. Used by 9 of top 10 pharmaceutical companies.
  • Patholytix Foresight AI-powered decision support tool for toxicologic pathology developed in partnership with Charles River Laboratories. Provides deeper insights into candidate efficacy during Lead Optimization and Dose Range Finding development stages, reducing pathologist review time by over 20%.
  • Patholytix 4.0 First DICOM-native platform for full archival and reconstruction of regulated digital studies, ensuring long-term accessibility and interoperability of GLP study data with native DICOMWSI for standardized digital slide storage.

Quantifiable outcome

  • 40% faster pathologist productivity while maintaining diagnostic accuracy
  • +9 more outcomes

Companies that use Deciphex

Customer profile

Named customers5 records

Segments3 records

Ideal customer profiles3 records

Deciphex technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration4 records

AI capability7 records

Feature7 records

Deciphex partnerships and signals

Strategic signal

Partnerships

Six partnerships are on record, tiered strategic, flagship and major.

  • ArterastrategicTechnology or Integration · 20 June 2025Collaboration to enable UK patients access to Artera's groundbreaking prostate cancer assay that combines hidden morphological signatures from digital pathology images with clinical findings for instant prognostic output.
  • Charles River LaboratoriesflagshipStrategic or Co-development Partner · 7 January 2025Major strategic partnership since March 2020 for co-development of AI tools to accelerate drug safety assessment. Completed first fully digital GLP study in May 2022. Strategic investor and commercial partner; collaborator on Patholytix Foresight AI decision support tool.
  • VICT3R Initiative Partners (33 organizations)majorStrategic or Co-development Partner · 16 September 2024Public-private partnership led by Pompeu Fabra University and Bayer AG. €28M IHI JU-funded initiative developing Virtual Control Groups to replace animals in concurrent control groups, reducing animal use by up to 25%. Deciphex contributes AI expertise for this 42-month project.
  • NovartisflagshipStrategic or Co-development Partner · 19 May 2022Series B investor and strategic collaborator on next-generation foundational AI models for multispecies lesion detection. Provides access to extensive non-clinical datasets from multi-species safety studies for AI model training.
  • Janssen PharmaceuticalsmajorStrategic or Co-development Partner · 19 May 2022Partner in €2M EU Fast Track to Innovation award for AI-driven workflows for preclinical pathology. Collaboration on accelerating development of AI-based workflows for preclinical pathology.
  • BigPicture ConsortiummajorStrategic or Co-development Partner · 28 January 2021EU IMI-funded pan-European initiative building world's largest digital pathology image repository (3 million slides) for AI model validation. Deciphex contributes to and draws from this repository for clinical and non-clinical AI development.

Scale indicators16 records

Recent moves9 records

Expansion highlights6 records

Deciphex competitors and assessment

Company assessment

Direct peers

  • Paige.AI: AI-native digital pathology company developing foundation models and diagnostic AI for clinical pathology. Directly comparable in technology stack (AI on whole-slide images), target customer (health systems and pathologists), and category leadership positioning.
  • PathAI: AI-powered pathology platform serving both clinical diagnostics and biopharma research, including preclinical safety assessment. Closest direct competitor to Deciphex's dual Diagnexia/Patholytix model with comparable pharma partnerships.
  • Ibex Medical Analytics: AI-driven cancer diagnostics platform for clinical pathology, deployed in health systems across the US, Europe, and Israel. Comparable clinical-side competitor with similar AI-on-whole-slide-image approach to Diagnexia.
  • Proscia: Digital pathology software company providing AI-enabled workflow and image management solutions to life sciences organizations and clinical labs. Comparable in platform/enterprise software positioning and customer overlap in pharma R&D.

Emerging players

  • Owkin: AI biotech company with significant pathology AI initiatives (including MOSAIQ for digital pathology) and biopharma partnerships. Partial overlap in foundation model strategy and pharma data collaborations.
  • Aiosyn: AI pathology company developing AI algorithms for clinical and research pathology applications. Emerging peer with overlapping AI-on-pathology focus, particularly in Europe.
  • Lunit: Medical AI company with pathology and radiology AI products serving clinical diagnostics and pharma research. Comparable in AI-driven cancer detection and pharma partnership strategy.

Broad incumbents

  • Roche Digital Pathology (Ventana): Incumbent digital pathology vendor (via Ventana/Roche) with integrated slide scanners, image management, and companion AI algorithms. Represents the primary enterprise-suite competitive threat to Deciphex's clinical workflow.
  • Philips Digital Pathology: Incumbent vendor of enterprise digital pathology solutions, already an integration partner for Deciphex. Comparable in NHS deployments and AI strategy, but operating at much broader scale across imaging and pathology.

Regional players

  • Unilabs: Major European diagnostics provider offering pathology and laboratory services across multiple countries. Comparable in clinical pathology services at scale and as a potential EU incumbent competitor to Diagnexia.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

Deciphex social profiles

Digital presence

Deciphex compliance and trust

Trust signal

Compliance8 records

Deciphex financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Deciphex leadership team

Management profile

Number of profiles

Profiles12 records

Deciphex subsidiaries and ownership

Company hierarchy

Subsidiaries4 records

Deciphex funding detail

Funding detail

Funding overview

Funding rounds8 records

Investors14 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Deciphex M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Deciphex

What does Deciphex do?

Deciphex operates two AI-powered digital pathology platforms. Diagnexia is a clinical diagnostics service connecting hospitals and NHS trusts to a global network of 250+ subspecialty pathologists, delivering rapid histopathology reporting with AI-driven quality controls. Patholytix is a GLP-compliant digital pathology platform for pharmaceutical companies and CROs that enables end-to-end digital preclinical safety studies, including the Patholytix Foresight AI decision support tool co-developed with Charles River Laboratories.

Is Deciphex a public or private company?

Deciphex is a private company. It is classified as venture growth investor backed and is currently operating.

When was Deciphex founded?

Deciphex was founded in 2017. It employs 101 to 250 people.

Where is Deciphex based?

Deciphex is headquartered in Dublin, Ireland, in the Europe region.

How does Deciphex make money?

Three revenue lines are on record. Diagnexia Clinical Diagnostics Services are the primary driver. The others are patholytix Pharmaceutical Research Platform and AI-Enhanced Workflow Services.

Who are Deciphex's main competitors?

Direct peers on record are Paige.AI, PathAI, Ibex Medical Analytics and Proscia. Emerging players are Owkin, Aiosyn and Lunit. Broad incumbents are Roche Digital Pathology (Ventana) and Philips Digital Pathology. Unilabs is listed as a regional player.

Does Deciphex have an API?

No public API is recorded for Deciphex.

What industry is Deciphex in?

Deciphex's product category is Digital Pathology Software. Its primary akta.pro industry code is HLACAMAB, Anatomic Pathology LIS & Digital Pathology Workflow. Its NAICS code is 621511 and its SIC code is 8071.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
TalkMarketsDigital Pathology Market: Regulatory Landscape and ComplianceThe global digital pathology market is projected to grow from USD 1.6 billion in 2026 to USD 3.0 billion by 2033, driven by increasing cancer cases and the integration of AI into diagnostic workflows. Key industry participants such as Charles River Laboratories, Deciphex, Proscia, Roche, and Fujifilm are expanding partnerships and acquiring assets to support this transition from traditional microscopy to digital systems.Business Wire BlogCharles River Accelerates Digital Pathology with AI-Powered End-to-End WorkflowCharles River Laboratories International, Inc. announced continued momentum in its digital pathology platform, delivering an end-to-end AI-enabled workflow that accelerates study timelines and enhances pathologist efficiency. The platform reduces pathology read times by an average of 20 percent and is expected to improve pathologist efficiency by more than 30 percent through AI-powered decision support, while cutting at least one week from standard pathology timelines. The company is deploying GLP-validated digital reviews and AI tools developed in partnership with Deciphex, with plans aligned to FDA guidance and the EU AI Act.Stock TitanCharles River AI pathology targets week off timelinesCharles River Laboratories International, Inc. announced continued momentum in its digital pathology platform, launching an AI-powered end-to-end workflow that integrates histology and pathology processes to cut at least one week from standard pathology timelines. Developed in partnership with Deciphex, the platform automates manual quality control steps and has already reduced pathology read times by an average of 20 percent, with plans to improve pathologist efficiency by more than 30 percent through AI decision support tools. The digital workflow also advances the 3Rs principles for animal welfare and aligns with FDA guidance and EU AI Act requirements for regulatory robustness.openPR.comDigital Pathology Market to Surpass US$ 4.2 Billion by 2035 Driven by AI Integration and Rising Demand for Advanced DiagnosticsThe global digital pathology market is projected to grow from US$ 1.1 billion in 2024 to over US$ 4.2 billion by 2035, representing a compound annual growth rate of 12.4%. Growth is driven by AI integration in diagnostic imaging, increasing adoption of telepathology solutions, and rising demand for advanced cancer diagnostics. Key industry developments include Charles River Laboratories' February 2025 collaboration with Deciphex to advance AI-powered digital pathology workflows, and Sectra's expansion of its digital pathology solution with Region Västra Götaland.MarketintellixIn-Depth Research on Computational Toxicology Solutions MarketMarket IntelliX published a market research report projecting the global Computational Toxicology Solutions market to grow from US$54.2 million in 2025 to US$98 million by 2031, representing a CAGR of 10.6% during the forecast period. The report identifies regulatory pressures from bodies such as EPA, FDA, and REACH, advancements in AI and machine learning, and cost-effectiveness compared to traditional in vivo testing as key market drivers. Key players analyzed include Instem (Leadscope), Lhasa Limited, MultiCASE, Inotiv, Simulations Plus Inc, Schrodinger, Aclaris, Evogene, Deciphex (Patholytix), and Exscientia across North America, Europe, Asia-Pacific, South America, and Middle East & Africa regions.The Currency“Transformative on multiple levels”: Irish medtech Deciphex opens Oxford test lab as it ramps up UK expansion - The CurrencyIrish medtech start-up Deciphex has opened its first pathological testing lab in Oxford, UK, after securing accreditation from the UK Accreditation Service (UKAS), following 18 months of work toward this goal. The company, which previously only reviewed pathological tests for the NHS, can now conduct its own tests in-house following the UKAS approval. CEO Donal O'Shea described the development as "transformative on multiple levels" as the company ramps up its UK expansion and plans to scale into the US market.360dxWith €46M in Funding, Deciphex Expands Digital Pathology Toolset and ReachDublin-based Deciphex raised €15 million in venture debt, adding to a recent €31 million Series C round, to expand its AI-driven digital pathology services and scale its Diagnexia platform into the US market. The company intends to address global pathologist shortages by leveraging a network of over 250 specialists and AI tools to triage cases and improve diagnostic efficiency for clients like the UK's NHS. While facing competition from major labs such as Quest Diagnostics and Labcorp in the US, Deciphex positions its model as a connectivity grid rather than a direct competitor.Claret-CapitalDeciphex Secures €15M Venture Debt Funding from Claret Capital Partners to Accelerate GrowthDeciphex secured €15 million in venture debt funding from Claret Capital Partners to accelerate its expansion in the United States and solidify market leadership in the UK. This strategic financing, which includes a €10 million immediate drawdown, supports the scaling of Deciphex’s AI-powered digital pathology platforms without diluting existing shareholders. The investment builds upon previous capital raises and aims to address global healthcare backlogs by enhancing diagnostic efficiency.DeciphexDeciphex Secures €15M Venture Debt Funding from Claret Capital Partners to Accelerate GrowthDeciphex, an AI-powered digital pathology company, has secured €15 million in venture debt funding from Claret Capital Partners, Europe's largest independent growth debt fund manager. The financing will accelerate the company's US market expansion and support its goal to become the leading histopathology reporting provider in the UK by 2027, while enabling continued scaling of its Diagnexia clinical diagnostics and Patholytix pharmaceutical research platforms without further dilution to existing shareholders. The funding builds on Deciphex's successful €31 million Series C round from January 2025, led by Molten Ventures.